Recently, the Department of Breast Surgery of Xiangya Hospital successfully joined the National Surgical Adjuvant Breast and Bowel Project (NSABP), a clinical trials cooperative group based in the United States, becoming the first member of the organization in Central South China (the second in China). This indicates that the clinical care and clinical trials offered by the Department have been in line with international standards, and the internationalization of the medical quality and clinical trials of the Department will be further promoted.
With the coordination and support of the International Exchanges & Cooperation Office of the hospital, Joan Goldberg, former CEO of NSABP, and her team visited the hospital for the first time on August 14, 2019 to conduct exchanges and field visits with the Department of Breast Surgery. On January 13, 2021, NSABP commissioned an expert team from the University of Pittsburgh Medical Center (UPMC) to come to the hospital for on-site evaluation. Upon detailed inspection and interviews, the clinical and research level of the Department was fully recognized. On March 22, 2021, Xiangya Hospital received the final approval and officially became a member organization of NSABP (ID number: 6059). In the future, the hospital can participate in or initiate global multi-center clinical trials.
NSABP, as a cooperative group conducting large-scale clinical trials of breast cancer and colorectal cancer, is currently the best platform for clinical trials of breast cancer in the world whose history can be traced back to 1957. Funded by the National Cancer Institute (NCI) under the USA National Institutes of Health (NIH), it is the main institution for cancer clinical research and training in the United States and even in the world, with its headquarter and biological statistics center located in Pittsburgh, USA. Its members include nearly 1,000 medical centers, university-affiliated hospitals and cancer research institutes in the United States, Canada, Australia and other countries. Since its inception, NSABP has enrolled more than 110,000 patients in clinical trials, with some important clinical trials having changed the clinical practice of breast cancer, making breast cancer treatment develop from a single surgical treatment mode to a widely accepted comprehensive treatment mode today and improving the prognosis of breast cancer patients.
In recent years, under the leadership of Director Wang Shouman, the Department of Breast Surgery has more than 10,000 discharges and more than 4,000 surgeries annually, the volume of breast-conserving therapy and postoperative breast reconstruction surgery has greatly increased. The breast reconstruction with autologous tissue including latissimus dorsi muscle and abdominal free flap, as well as prosthetic breast reconstruction and other operations in various ways such as one-step and two-step methods have been carried out. The Department has led the establishment of the COE-RBCC: Center of Excellence-Regional Breast Cancer Center. It won the national championship of the "Breast Cancer Discipline Elite Competition of Bethune Young and Middle-aged Doctor Talent Training Program" in 2018 and 2019. The Department has led and undertaken a number of Phase I clinical trials, participated in more than 10 large-scale clinical trials in Phase II, III and IV at home and abroad, continuously improved the quality and management level of clinical trials, and practiced standardized treatment of breast cancer.